NSABP Objects to “Closed Process” For Review Of P-4 Breast Cancer Chemoprevention Trial.
NCI Barred PI Wolmark And Its Own Prevention Staff From Ad Hod Meeting.
NCI Director To Decide Fate Of P-4 After NCAB Meeting In June.
Paul Goss, Patricia Ganz Discuss Breast Cancer Prevention Trials.
Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.
Trending Stories
- “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
- How City of Hope is turning microbiome science into better cancer care
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members









